In an open-label randomized trial, postexposure doxycycline significantly reduced bacterial STI incidence in at-risk MSM and transgender women who were on PrEP or were living with HIV.
With the rising incidence of bacterial sexually transmitted infections (STIs) in many countries, particularly among men who have sex with men (MSM) and transgender women, better interventions are needed. Postexposure prophylaxis (PEP) with doxycycline (DOXY) after condomless sex was shown to be beneficial against syphilis and chlamydia but not gonorrhea in a study conducted in France (NEJM JW Infect Dis Jan 2 2018 and Lancet Inf Dis 2017 Dec 8; [e-pub]). Now, researchers have evaluated the same strategy in MSM or transgender women who were on preexposure prophylaxis (PrEP) or were living with HIV (PLWH) in the U.S. In all, 501 participants (327 [PrEP group] and 174 [PLWH group]) were randomized to a single 200-mg dose of DOXY PEP or standar…
Reviewing Author
DisclosuresConsultant/Advisory BoardViiV Advisory Board
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes
DisclosuresConsultant/Advisory BoardViiV Advisory Board
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes